Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Your search for Infliximab Hidradenitis Suppurtiva returned no results
Showing 1 result for infliximab hidradenitis suppurativa

  1. Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

    Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA392